Synthetic Biology Market Hits $19.75B, Genome Engineering Leads at 33%
Synthetic biology is already a $20B market, and genome engineering owns a third of it — with Asia-Pacific accelerating fast enough to reshape where the next decade of biotech gets built.
Explanation
Mordor Intelligence pegs the synthetic biology market at $19.75 billion in 2025, with projections pointing to significant expansion through 2031. Genome engineering — the deliberate rewriting of DNA to give organisms new functions — commands the largest slice at 33.21% of the total market.
Synthetic biology (synbio) is the discipline of designing and building biological systems the way engineers design circuits: modular, programmable, and increasingly cheap to iterate. It underpins everything from lab-grown meat and biofuels to cancer therapies and industrial enzymes.
The Asia-Pacific region is flagged as the fastest-growing geography. That's not a surprise given China's aggressive state investment in biotech infrastructure, India's expanding CRO (contract research organization) ecosystem, and Southeast Asia's push into agricultural biotech. The center of gravity for synbio manufacturing and R&D is drifting east.
Why care now? Because the market structure — one dominant segment, one dominant growth region — tells you where capital and talent will concentrate over the next five years. Companies and investors still treating synbio as a Western-centric story are already behind.
The honest caveat: this is a Mordor Intelligence market report distributed via PR Newswire, a format that routinely inflates TAM figures and smooths over competitive complexity. The headline numbers are directionally useful, not gospel. Watch for independent validation from deal flow data and public company earnings before anchoring strategy to these projections.
Mordor Intelligence's 2026–2031 synthetic biology market report places the 2025 baseline at $19.75B, with genome engineering holding a 33.21% segment share — roughly $6.6B — ahead of DNA synthesis, biological parts, and enabling tools categories. The report identifies Asia-Pacific as the fastest-growing region, consistent with trends visible in public funding data: China's 14th Five-Year Plan explicitly targets synthetic biology as a strategic sector, and APAC-based CDMOs are increasingly capturing Western pharma outsourcing contracts.
The genome engineering dominance is structurally defensible. CRISPR-based platforms (Cas9, base editors, prime editors), TALENs, and large-scale metabolic engineering projects all fall under this umbrella, and the tooling cost curve continues to compress. Per-base DNA synthesis costs have dropped ~100,000x over two decades; that deflationary pressure expands addressable applications faster than any single product category.
What the report doesn't surface — and what matters more to domain readers — is segment margin differentiation. Genome engineering tools (Benchling, Twist Bioscience, Ginkgo Bioworks' platform plays) carry very different unit economics than downstream application verticals like industrial biotech or biopharma. Lumping them into one share figure obscures where value actually accrues.
The APAC growth story also has a bifurcation worth tracking: China is scaling manufacturing and platform infrastructure, while South Korea and Singapore are building higher-margin specialty biotech clusters. These are not the same growth thesis.
Open questions that would sharpen the picture: What's the CAGR implied by the 2031 target (the excerpt cuts off before the number)? How does the report handle the Ginkgo Bioworks-style platform collapse in valuations since 2021 — does it adjust for the gap between synbio hype-cycle peaks and actual revenue? A falsifier for the APAC thesis would be sustained regulatory tightening on GMO-derived products in key export markets, which could slow commercialization timelines materially. Incremental signal overall, but useful as a baseline anchor for competitive landscape mapping.
Reality meter
Why this score?
Trust Layer Score basis
A detailed evidence breakdown is being added. For now, the score basis is the source list below and the reality meter above.
- 46 sources on file
- Avg trust 42/100
- Trust 40–95/100
Time horizon
Community read
Glossary
- Genome engineering
- The direct manipulation of an organism's DNA using molecular tools like CRISPR, TALENs, or base editors to modify genes for research, therapeutic, or industrial purposes.
- CRISPR
- A gene-editing technology that uses molecular scissors (Cas9 and related proteins) to precisely cut and modify DNA sequences in living cells.
- CDMOs
- Contract Development and Manufacturing Organizations that provide outsourced drug development and manufacturing services to pharmaceutical companies.
- DNA synthesis
- The artificial creation of DNA molecules from chemical components, enabling the design and production of custom genetic sequences for research and therapeutic applications.
- Metabolic engineering
- The modification of cellular metabolic pathways to optimize the production of desired compounds, such as biofuels or pharmaceuticals, in microorganisms or cells.
- Unit economics
- The financial metrics that measure the profitability and cost structure of individual products or services, such as revenue per unit minus direct costs.
What's your read?
Your read shapes future topic weighting.
Your vote feeds topic weights, community direction and future prioritisation. Open community direction
Sources
- Tier 3 Synthetic Biology Market Analysis 2026-2031: Genome Engineering Accounts for 33.21% Share, with Asia-Pacific as the Fastest-Growing Region, Says Mordor Intelligence
- Tier 3 Biotechnology News -- ScienceDaily
- Tier 3 Colossal Biosciences announces ‘de-extinction’ plan for African bluebuck | CNN
- Tier 3 Clarkson University Researchers Contribute to Breakthrough Biosensor Technology Published in Nature Biotechnology | Clarkson University
- Tier 3 Biotech and Pharma Industry News | BioPharma Dive
- Tier 3 ScienceDaily: Your source for the latest research news
- Tier 3 Fierce Biotech News & Reports
- Tier 1 Nature Biotechnology
- Tier 3 2024 in science - Wikipedia
- Tier 3 Top Biotech Startups 2026: An Analysis of Emerging Trends | IntuitionLabs
- Tier 3 Study: CRISPR gene editing leads to improvements in vision for people with inherited blindness | Ophthalmology Times - Clinical Insights for Eye Specialists
- Tier 3 A one-time treatment tweaked their genes — and lowered their cholesterol
- Tier 3 Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing - Intellia Therapeutics
- Tier 3 Potential Cure for HIV from CRISPR Gene Editing in Phase 1/2 Clinical Trial | Contagion Live
- Tier 3 Milestone for Crispr: First-of-Its-Kind Gene Editing Treatment Successfully Passes Clinical Trial
- Tier 3 CRISPR gene editing - Wikipedia
- Tier 3 Intellia CRISPR drug succeeds in late-stage study against rare swelling disorder | BioPharma Dive
- Tier 3 Discovery broadens scope of use of CRISPR gene editing | ScienceDaily
- Tier 3 Scientists just made CRISPR three times more effective | ScienceDaily
- Tier 3 Synthetic Biology Market Size, Share, Industry Growth 2035
- Tier 3 Synthetic Biology Market Size, Share & Growth Trends 2035
- Tier 3 Flagship Pioneering Launches Serif Biomedicines to Establish Modified DNA as a New Biotechnology
- Tier 3 SynbiTECH 2026 | The Must-Attend Synthetic Biology Conference
- Tier 3 2026 Synthetic Biology: Engineering, Evolution, & Design (SEED) | AIChE
- Tier 3 Synthetic Biology Market worth $31.52 billion in 2029 | Press Releases | reformer.com
- Tier 3 Global DNA Read, Write and Edit Market to Surge to $67.7 Billion by 2030, Driven by CRISPR Advances, Genomic Diagnostics and Expanding Clinical Applications
- Tier 3 North America Gene Synthesis Market Outlook 2026-2034
- Tier 3 Synthetic Biology Product Market is Going to Boom | Amyris , Zymergen
- Tier 3 List of Funded Biotech Startups (2026) - Fundraise Insider
- Tier 3 Early-stage funding slumps toward post-pandemic low, piling more pressure on biotech startups
- Tier 3 The Week’s 10 Biggest Funding Rounds: SiFive Leads With $400M For Custom Chip Designs As Aviation, Biotech And Defense Startups Also Raise Big
- Tier 3 1,200+ Funded Biotech Startups 2026 | Verified Contacts
- Tier 3 Biotech Valuation Benchmarks for Series A and B in 2026
- Tier 3 The Week’s 10 Biggest Funding Rounds: AI, Autonomy And Biotech Top The Ranks
- Tier 3 Biotechnology Startup Funding 2025-2026 – New Market Pitch
- Tier 3 Jeito Capital, prominent biotech investor, raises $1.2B for next fund | BioPharma Dive
- Tier 3 Stanford's James Zou targets $1B valuation for AI physiology startup backed by Nature-published research and FDA-cleared cardiac AI
- Tier 3 DNA origami vaccines could be the next leap beyond mRNA | ScienceDaily
- Tier 1 Engineered cells as programmable mRNA delivery vehicles | Nature Reviews Bioengineering
- Tier 3 AI, CRISPR, and mRNA Driving Biotech’s Smartest Decade Yet | BioPharm International
- Tier 3 New Research Challenges Understanding of mRNA Vaccines and Establishes Innovative Way to Make Them More Effective | Mount Sinai - New York
- Tier 3 mRNA Delivery Technology Landscape 2026 — PatSnap Eureka | PatSnap
- Tier 3 Next-generation neoantigen mRNA vaccines: Immuno-engineering strategies for precision cancer immunotherapy | Cellular Oncology | Springer Nature Link
- Tier 3 After a year of turmoil, cancer researchers see promising signs for mRNA vaccines | CNN
- Tier 3 mRNA Therapeutics Market Size to Hit USD 83.49 Billion by 2035 - BioSpace
- Tier 3 Next-generation neoantigen mRNA vaccines: Immuno-engineering strategies for precision cancer immunotherapy - PMC
Optional Submit a prediction Optional: add your prediction on the core question if you like.
Prediction
Will Asia-Pacific surpass North America in synthetic biology market share before 2031?